HC Wainwright Reiterates Buy Rating for Affimed (NASDAQ:AFMD)

HC Wainwright restated their buy rating on shares of Affimed (NASDAQ:AFMD) in a research note published on Friday morning,Benzinga reports. The firm currently has a $10.00 target price on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $16.00.

Affimed Stock Down 4.7 %

AFMD stock traded down $0.17 during midday trading on Friday, reaching $3.48. 132,609 shares of the company’s stock traded hands, compared to its average volume of 266,981. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. Affimed has a 52-week low of $2.92 and a 52-week high of $8.95. The stock’s 50-day moving average is $3.49 and its 200 day moving average is $4.52.

Affimed (NASDAQ:AFMD) last announced its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $1.67 million. As a group, sell-side analysts expect that Affimed will post -4.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Affimed

A number of hedge funds have recently made changes to their positions in the business. Choreo LLC bought a new stake in Affimed in the 2nd quarter valued at $54,000. Jane Street Group LLC purchased a new stake in shares of Affimed in the third quarter worth about $44,000. FMR LLC boosted its stake in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares during the last quarter. Intellectus Partners LLC increased its stake in Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the last quarter. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.